January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting ...

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due to adverse events (AEs), including experiences where these adjustments ...

Dr. Mohan discusses with Nurse Goff and Nurse Brigle the prevention and management of infections and neurological toxicities in patients receiving bispecific therapies, with a particular focus on the ...

Cytokine Release Syndrome (CRS) is a major concern in CAR-T therapy. How do you approach the grading and management of CRS? Which strategies have you found most effective for reducing the severity of ...